Labcorp Holdings Inc. (LH)
| Market Cap | 21.34B |
| Revenue (ttm) | 13.95B |
| Net Income (ttm) | 876.50M |
| Shares Out | 82.19M |
| EPS (ttm) | 10.46 |
| PE Ratio | 24.85 |
| Forward PE | 14.61 |
| Dividend | $2.88 (1.11%) |
| Ex-Dividend Date | May 29, 2026 |
| Volume | 621,109 |
| Open | 265.39 |
| Previous Close | 263.43 |
| Day's Range | 258.56 - 267.14 |
| 52-Week Range | 218.76 - 293.72 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 311.33 (+19.89%) |
| Earnings Date | Apr 30, 2026 |
About LH
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target speci... [Read more]
Financial Performance
In 2025, Labcorp Holdings's revenue was $13.95 billion, an increase of 7.25% compared to the previous year's $13.01 billion. Earnings were $876.50 million, an increase of 17.49%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for LH stock is "Buy." The 12-month stock price target is $311.33, which is an increase of 19.89% from the latest price.
News
Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
BURLINGTON, N.C., April 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technol...
d-wise Appoints 2x-CEO, ex-Labcorp Head of Software Solutions to Drive Next Phase of Strategy & Growth
BOSTON--(BUSINESS WIRE)--d-wise (an Instem company), a leader in statistical computing infrastructure and clinical trial transparency, today announced the appointment of Christine Oliver as its Presid...
Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes
First FDA-cleared rapid fentanyl test of its kind made in the United States designed to help emergency department and hospital teams act quickly when every second counts Fentanyl Urine Visual Test is ...
Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research
Platform leverages agentic AI and diverse healthcare datasets to transform and speed drug development BURLINGTON, N.C., April 14, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative...
Children's Hospital of Philadelphia and Labcorp Announce a Collaboration to Accelerate Access to Advanced Pediatric Diagnostics Nationwide
Collaboration aims to speed the discovery, development and national availability of specialized pediatric diagnostics BURLINGTON, N.C. and PHILADELPHIA, April 13, 2026 /PRNewswire/ -- Labcorp (NYSE: L...
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C., April 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has d...
Labcorp to Announce First Quarter Financial Results on April 30, 2026
BURLINGTON, N.C., March 31, 2026 /PRNewswire/ -- Labcorp Holdings Inc.
Illumina and Labcorp expand collaboration to broaden access to precision oncology testing
SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collabo...
Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide
AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration and patien...
Labcorp Holdings Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 7% revenue and 13% adjusted EPS growth, driven by Diagnostics and Central Labs. 2026 guidance calls for 5.4% revenue growth at midpoint, 9% adjusted EPS growth, and margin expansion, supported by robust specialty testing and acquisitions.
Labcorp forecasts upbeat annual profit on strong demand for diagnostic products
Laboratory services provider Labcorp forecast annual profit above Wall Street estimates on Tuesday, banking on robust demand for its diagnostic tests.
Labcorp Announces 2025 Fourth Quarter and Full Year Results
Company Provides 2026 Guidance Financial results from Operations versus 2024: Revenue: Q4 of $3.52 billion vs $3.33 billion; Full year of $13.95 billion vs $13.01 billion Diluted EPS: Q4 of $1.98 vs $...
Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care
Elecsys ® pTau-181 test helps clinicians rule out Alzheimer's disease by identifying patients unlikely to have amyloid pathology Now available nationwide in primary care settings for patients aged 55 ...
Labcorp Appoints John H. Sampson, M.D.
BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H.
Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026
BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth...
Labcorp Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference
Key growth in 2025 was driven by specialty testing, hospital acquisitions, and successful integration of Invitae, leading to new cancer diagnostics. AI and automation are enhancing efficiency, while strong payer relationships and disciplined M&A support future growth. PAMA and Results legislation remain key regulatory variables.
Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk
Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA non-sm...
Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs
SAN JOSE, Calif.--(BUSINESS WIRE)--Today, Visby Medical announced two new relationships that will expand national access to the Visby Women's Sexual Health Test, the first, at-home, FDA-authorized PCR...
NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp
TOLEDO, Ohio, Jan. 8, 2026 /PRNewswire/ -- NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of th...
Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C., Dec. 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside...
Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks
ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Lab...
Community Health Systems Completes Sale of Select Outreach Laboratory Assets to Labcorp
FRANKLIN, Tenn. & BURLINGTON, N.C.--(BUSINESS WIRE)--Community Health Systems, Inc. (the “Company”) (NYSE: CYH) announced today that its subsidiary, CHS/Community Health Systems, Inc. (CHS), has compl...
Labcorp Appoints Victor Bulto to Board of Directors
Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: L...
Labcorp® Plasma Detect™ Clinical Studies Featured in Nature Medicine and Clinical Cancer Research
Studies demonstrate Labcorp Plasma Detect MRD Technology can inform treatment strategies and advance cancer research BURLINGTON, N.C. , Nov. 19, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leade...
Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research
DURHAM, N.C. and SEOUL, South Korea , Nov. 17, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and compre...